JOPIC
Journal of Pulmonology and Intensive Care

The JoPIC is an independent-unbiased, peer-reviewed, and open-access journal of current national and international issues and reviews for original clinical and experimental research, interesting case reports, surgical techniques, differential diagnoses, editorial opinions, letters to the editor, and educational papers in pulmonology, thoracic surgery, occupational diseases, allergology, and intensive care medicine.

eISSN: 2980-0803
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
The prognostic value of PET/CT-derived volumetric parameters for postoperative recurrence in resected non-small cell lung cancer
Abstract
Aims: Non-small-cell lung cancer (NSCLC) recurrence is high even after complete surgical resection. This study aimed to investigate the relationship between recurrence and 18F-fluorodeoxyglucose positron emission tomography computed tomography parameters and to determine prognostic factors.
Methods: Stage I–II NSCLC, confirmed through pathology after undergoing surgical resection were retrospective analyzed. Before surgery, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were derived by applying SUVmax-based thresholds of 2.5 and 42%. Data regarding demographics, clinicopathological features, and tumor characteristics were gathered. Kaplan–Meier method was used for disease-free survival (DFS) and overall survival rates. Prognostic factors causing recurrence were evaluated using univariate and multivariate Cox regression analysis.
Results: The average age of the 179 people included in the study was 61.24 years. Median follow up time was 50 months. Recurrence occurred in 38.5% of the patients. Prognostic factors for recurrence were larger tumor size, visceral pleural invasion, and PL2 involvement. When stratified by histology, MTV measured using SUVmax thresholds of 2.5 and 42% was significantly higher in patients with recurrence in the squamous cell carcinoma subgroup. In univariate analysis, high MTV42% was associated with shorter DFS. In multivariate analysis, MTV2.5 remained an independent predictor of DFS. SUVmax and TLG were not independently associated with DFS.
Conclusion: Disease-free survival was influenced by tumor size and the presence of pleural invasion. MTV may serve as a complementary prognostic biomarker to TNM staging in patients with early-stage NSCLC.

Keywords : Disease free survival, NSCLC, recurrence, SUVmax, total lesion glycolysis, metabolic tumor volume

Download Article


1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023.CA Cancer J Clin. 2023;73(1):17-48. <a href="https://doi.org/10.3322/caac.21763">doi:10.3322/caac.21763</a>
2. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243-1260. <a href="https://doi.org/10.1097/JTO.0000000000000630">doi:10.1097/JTO.0000000000000630</a>
3. Simeone JC, Nordstrom BL, Patel K, Klein AB. Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting.Future Oncol. 2019;15(30):3491-3502. <a href="https://doi.org/10.2217/fon-2019-0348">doi:10.2217/fon-2019-0348</a>
4. Edwards JG, Chansky K, Van Schil P, et al. The IASLC lung cancer staging project: analysis of resection margin status and proposals for residual tumor descriptors for non-small cell lung cancer.J Thorac Oncol. 2020;15(3):344-359. <a href="https://doi.org/10.1016/j.jtho.2019.10.019">doi:10.1016/j.jtho.2019.10.019</a>
5. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer.J Thorac Oncol. 2016;11(1):39-51. <a href="https://doi.org/10.1016/j.jtho.2015.09.009">doi:10.1016/j.jtho.2015.09.009</a>
6. Strauss LG, Conti PS. The applications of PET in clinical oncology.J Nucl Med. 1991;32(4):623-650
7. Casali C, Cucca M, Rossi G, et al. The variation of prognostic significance of maximum standardized uptake value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected non-small cell lung carcinoma.Lung Cancer. 2010;69(2):187-193. <a href="https://doi.org/10.1016/j.lungcan.2009.10.015">doi:10.1016/j.lungcan.2009.10.015</a>
8. Liu J, Dong M, Sun X, Li W, Xing L, Yu J. Prognostic value of 18F-FDG PET/CT in surgical non-small cell lung cancer: a meta-analysis.PLoS One. 2016;11(1):e0146195. <a href="https://doi.org/10.1371/journal.pone.0146195">doi:10.1371/journal.pone.0146195</a>
9. Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CY. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ((18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).Eur J Nucl Med Mol Imaging. 2010;37(4):691-698. <a href="https://doi.org/10.1007/s00259-009-1291-x">doi:10.1007/s00259-009-1291-x</a>
10. Wang D, Koh ES, Descallar J, Pramana A, Vinod SK, Ho Shon I. Application of novel quantitative techniques for fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer.Asia Pac J Clin Oncol. 2016;12(4):349-358. <a href="https://doi.org/10.1111/ajco.12587">doi:10.1111/ajco.12587</a>
11. Hyun SH, Choi JY, Kim K, et al. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg. 2013;257(2):364-370. <a href="https://doi.org/10.1097/SLA.0b013e318262a6ec">doi:10.1097/SLA.0b013e318262a6ec</a>
12. Park SY, Cho A, Yu WS, et al. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer. J Nucl Med. 2015;56(1):45-49. <a href="https://doi.org/10.2967/jnumed.114.147561">doi:10.2967/jnumed.114.147561</a>
13. Travis WD, Brambilla E, Rami-Porta R, et al. Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol. 2008; 3(12):1384-1390. <a href="https://doi.org/10.1097/JTO.0b013e31818e0d9f">doi:10.1097/JTO.0b013e31818e0d9f</a>
14. Seban RD, Mezquita L, Berenbaum A, et al. Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors.Eur J Nucl Med Mol Imaging. 2020;47(5):1147-1157. <a href="https://doi.org/10.1007/s00259-019-04615-x">doi:10.1007/s00259-019-04615-x</a>
15. Sugimura H, Nichols FC, Yang P, et al. Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg. 2007;83(2):409-418. <a href="https://doi.org/10.1016/j.athoracsur.2006.08.046">doi:10.1016/j.athoracsur.2006.08.046</a>
16. Kelsey CR, Marks LB, Hollis D, et al. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients.Cancer. 2009;115(22):5218-5227. <a href="https://doi.org/10.1002/cncr.24625">doi:10.1002/cncr.24625</a>
17. Hung JJ, Hsu WH, Hsieh CC, et al. Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence.Thorax. 2009;64(3):192-196. <a href="https://doi.org/10.1136/thx.2007.094912">doi:10.1136/thx.2007.094912</a>
18. Kim DH, Son SH, Kim CY, et al. Prediction for recurrence using F-18 FDG PET/CT in pathologic N0 lung adenocarcinoma after curative surgery. Ann Surg Oncol. 2014;21(2):589-596. <a href="https://doi.org/10.1245/s10434-013-3270-5">doi:10.1245/s10434-013-3270-5</a>
19. Hendriksen BS, Ortiz BA, Wigle DA, et al. Risk factors and survival associated with lung cancer recurrence after curative-intent surgery: beyond TNM pathological staging.J Thorac Dis. 2025;17(11):10285-10297. <a href="https://doi.org/10.21037/jtd-2025-1404">doi:10.21037/jtd-2025-1404</a>
20. Taylor MD, Nagji AS, Bhamidipati CM, et al. Tumor recurrence after complete resection for non-small cell lung cancer.Ann Thorac Surg. 2012;93(6):1813-1821. <a href="https://doi.org/10.1016/j.athoracsur.2012.03.031">doi:10.1016/j.athoracsur.2012.03.031</a>
21. Chou HP, Lin KH, Huang HK, et al. Prognostic value of positron emission tomography in resected stage IA non-small cell lung cancer. Eur Radiol. 2021;31(10):8021-8029. <a href="https://doi.org/10.1007/s00330-021-07801-4">doi:10.1007/s00330-021-07801-4</a>
22. Hung JJ, Jeng WJ, Hsu WH, Chou TY, Lin SF, Wu YC. Prognostic significance of the extent of visceral pleural invasion in completely resected node-negative non-small cell lung cancer. Chest. 2012;142(1): 141-150. <a href="https://doi.org/10.1378/chest.11-2552">doi:10.1378/chest.11-2552</a>
23. Tian D, Pei Y, Zheng Q, et al. Effect of visceral pleural invasion on the prognosis of patients with lymph node negative non-small cell lung cancer. Thorac Cancer. 2017;8(2):97-105. <a href="https://doi.org/10.1111/1759-7714.12412">doi:10.1111/1759-7714.12412</a>
24. Altorki N, Wang X, Damman B, et al. Recurrence of non-small cell lung cancer with visceral pleural invasion: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2024;10(9):1179-1186. <a href="https://doi.org/10.1001/jamaoncol.2024.2491">doi:10.1001/jamaoncol.2024.2491</a>
25. Melloni G, Gajate AM, Sestini S, et al. New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer. Eur J Surg Oncol. 2013; 39(11):1254-1261. <a href="https://doi.org/10.1016/j.ejso.2013.07.092">doi:10.1016/j.ejso.2013.07.092</a>
26. Shang J, Duan X, He Y, et al. Prognostic value of integrating CT morphological features and PET volumetric metabolic parameters in surgically resected stage IA non-small cell lung cancer: a two-center retrospective study. Cancer Imaging. 2025;25(1):134. <a href="https://doi.org/10.1186/s40644-025-00954-1">doi:10.1186/s40644-025-00954-1</a>
27. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004;22(16):3255-3260. <a href="https://doi.org/10.1200/JCO.2004.11.109">doi:10.1200/JCO.2004.11.109</a>
28. Kim K, Kim SJ, Kim IJ, Kim YS, Pak K, Kim H. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer. Nucl Med Commun. 2012;33(6): 613-620. <a href="https://doi.org/10.1097/MNM.0b013e328351d4f5">doi:10.1097/MNM.0b013e328351d4f5</a>
29. Mamede M, Higashi T, Kitaichi M, et al. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia. 2005;7(4):369-379. <a href="https://doi.org/10.1593/neo.04577">doi:10.1593/neo.04577</a>
30. Ito T, Noguchi Y, Satoh S, Hayashi H, Inayama Y, Kitamura H. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol. 1998;11(5):437-443
31. Ganeshan B, Goh V, Mandeville HC, Ng QS, Hoskin PJ, Miles KA. Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. Radiology. 2013;266(1):326-336. <a href="https://doi.org/10.1148/radiol.12112428">doi:10.1148/radiol.12112428</a>
32. Miyoshi K, Moriyama S, Kunitomo T, Nawa S. Prognostic impact of intratumoral vessel invasion in completely resected pathologic stage I non-small cell lung cancer.J Thorac Cardiovasc Surg. 2009;137(2):429-434. <a href="https://doi.org/10.1016/j.jtcvs.2008.07.007">doi:10.1016/j.jtcvs.2008.07.007</a>
33. Kadota K, Colovos C, Suzuki K, et al. FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma. Ann Surg Oncol. 2012;19(11):3598-3605. <a href="https://doi.org/10.1245/s10434-012-2414-3">doi:10.1245/s10434-012-2414-3</a>
34. Lee H, Choi YL, Kim HK, et al. Prognostic significance of volumetric parameters based on FDG PET/CT in patients with lung adenocarcinoma undergoing curative surgery. Cancers (Basel). 2023; 15(17):4380. <a href="https://doi.org/10.3390/cancers15174380">doi:10.3390/cancers15174380</a>
35. Dosani M, Yang R, McLay M, et al. Metabolic tumour volume is prognostic in patients with non-small-cell lung cancer treated with stereotactic ablative radiotherapy. Curr Oncol. 2019;26(1):e57-e63. <a href="https://doi.org/10.3747/co.26.4167">doi:10.3747/co.26.4167</a>
36. Sasaki R, Komaki R, Macapinlac H, et al. [18F] fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005;23(6):1136-1143. <a href="https://doi.org/10.1200/JCO.2005.06.129">doi:10.1200/JCO.2005.06.129</a>
37. Wen W, Piao Y, Xu D, Li X. Prognostic value of MTV and TLG of 18F-FDG PET in patients with stage I and II non-small-cell lung cancer: a meta-analysis.Contrast Media Mol Imaging. 2021;2021:7528971. <a href="https://doi.org/10.1155/2021/7528971">doi:10.1155/2021/7528971</a>
38. Pellegrino S, Fonti R, Pulcrano A, Del Vecchio S. PET-based volumetric biomarkers for risk stratification of non-small cell lung cancer patients. Diagnostics (Basel). 2021;11(2):210. <a href="https://doi.org/10.3390/diagnostics11020210">doi:10.3390/diagnostics11020210</a>
Article available in :
Volume 4, Issue 3, 2026
Page : 79-87
https://doi.org/10.51271/JOPIC-0085
Article Information
Received : 25 Haz 2026
Accepted : 27 Tem 2026
Published : 20 Ağu 2026
Corresponding Author :

Ezgi Erdem Türe: Department of Chest Diseases, Ankara Etlik City Hospital, Ankara, Turkiye

[email protected]
Citation : Erdem Türe E, Özmen Ö, Akın Kabalak P, Demiröz ŞM. The prognostic value of PET/CT-derived volumetric parameters for postoperative recurrence in resected non-small cell lung cancer. J Pulmonol Intens Care. 2026;4(3):79-87. doi:10.51271/JOPIC-0085

Read: 3
Download : 2
Cited: 0
_Footer